Untitled

Dembri, Assia; Montisci, Marie-Jeanne; Gantier, Jean-Charles; Chacun, Hélène; Ponchel, Gilles

doi:10.1023/a:1011050209986

Cited by 61 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, with the exception of a very early attempt in 2001 [112], literature reports suggesting or proving the feasibility of specifically targeting the gut mucosa using DDS are lacking. This 2001 study achieved a four-fold higher AZT gut mucosa concentrations 90 minutes after oral dosing in rat using a poly(isohexylcyanoacrylate) NP formulation compared to free AZT.…”

Section: Introductionmentioning

confidence: 99%

Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment

Nelson

Zhang

Ganapathi

et al. 2015

Journal of Controlled Release

View full text Add to dashboard Cite

The year 2016 will mark an important milestone - the 35th anniversary of the first reported cases of HIV/AIDS. Antiretroviral Therapy (ART) including Highly Active Antiretroviral Therapy (HAART) drug regimens is widely considered to be one of the greatest achievements in therapeutic drug research having transformed HIV infection into a chronically managed disease. Unfortunately, the lack of widespread preventive measures and the inability to eradicate HIV from infected cells highlight the significant challenges remaining today. Moving forward there are at least three high priority goals for anti-HIV drug delivery (DD) research: (1) to prevent new HIV infections from occurring, (2) to facilitate a functional cure, i.e., when HIV is present but the body controls it without drugs and (3) to eradicate established infection. Pre-exposure Prophylaxis (PrEP) represents a significant step forward in preventing the establishment of chronic HIV infection. However, the ultimate success of PrEP will depend on achieving sustained antiretroviral (ARV) tissue concentrations and will require strict patient adherence to the regimen. While first generation long acting/extended release (LA/ER) DDS currently in development show considerable promise, significant DD treatment and prevention challenges persist. First, there is a critical need to improve cell specificity through targeting in order to selectively achieve efficacious drug concentrations in HIV reservoir sites to control/eradicate HIV as well as mitigate systemic side effects. In addition, approaches for reducing cellular efflux and metabolism of ARV drugs to prolong effective concentrations in target cells need to be developed. Finally, given the current understanding of HIV pathogenesis, next generation anti-HIV DDS need to address selective DD to the gut mucosa and lymph nodes. The current review focuses on the DDS technologies, critical challenges, opportunities, strategies, and approaches by which novel delivery systems will help iterate towards prevention, functional cure and eventually the eradication of HIV infection.

show abstract

Section: Introductionmentioning

confidence: 99%

Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment

Nelson

Zhang

Ganapathi

et al. 2015

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…Previous papers that have evaluated the kinetics of hydrophilic drug release from both lipid nanoparticles, report burst release profiles in which most of the drug is released within the first hour [13,38]. Other papers evaluating drug release kinetics from polymeric particles show biphasic release – including an initial burst release phase, which may be due to surface-associated drug [39].…”

Section: Discussionmentioning

confidence: 99%

Biophysical characterization of small molecule antiviral-loaded nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application

et al. 2016

View full text Add to dashboard Cite

Nanocarriers are versatile vehicles for drug delivery, and emerging as platforms to formulate and deliver multiple classes of antiretroviral (ARV) drugs in a single system. Here we describe the fabrication of hydrogel-core and lipid-shell nanoparticles (nanolipogels) for the controlled loading and topical, vaginal delivery of maraviroc (MVC) and tenofovir disoproxil fumarate (TDF), two ARV drugs with different mechanisms of action that are used in the treatment of HIV. The nanolipogel platform was used to successfully formulate MVC and TDF, which produced ARV drug-loaded nanolipogels that were characterized for their physical properties and antiviral activity against HIV-1 BaL in cell culture. We also show that administration of these drug carriers topically to the vaginal mucosa in a murine model leads to antiviral activity against HIV-1 BaL in cervicovaginal lavages. Our results suggest that nanolipogel carriers are promising for the encapsulation and delivery of hydrophilic small molecule ARV drugs, and may expand the nanocarrier systems being investigated for HIV prevention or treatment.

show abstract

“…46 Furthermore, AZTloaded poly-(isohexylcyanoacrylate) nanospheres displayed promising features to target the antiviral to the epithelium of the intestine and gut-associated lymphoid tissues, which are the main reservoirs of HIV in the gastrointestinal (GI) tract. 47 The preparation of pH sensitive NPs was an interesting alternative to improve the bioavailability of HIV-1 protease inhibitor with a very low water-solubility. In this sense, nanoparticles made of the poly(methacrylic acid-coethylacrylate) copolymer Eudragit® L100-55 were orally administered to dogs of beagle breed and led to an increase in plasma concentrations due to a specific release of the antiviral near its absorption site.…”

Section: Antiviral Drugsmentioning

confidence: 99%

Nanobiotechnology Solutions againstAedes aegypti

Islan

Durán

Castro

2016

Journal of the Brazilian Chemical Society

View full text Add to dashboard Cite

United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/ World Bank/World Health Organization (WHO) implemented the Training in Tropical Diseases (TDR) program with excellent results; however, due to current challenges, this active program requires new and innovative solutions. Nowadays, Aedes aegyptis-borne diseases can be added among neglected diseases. Surveillance and control must be considered owing to a great risk of infection with dengue, chikungunya and zika viruses. Although investigations on several vaccines are in progress, new insights in term of development of drugs that evade from resistance are of paramount importance. Nanobiotechnology appears as one of the most innovative strategy in the search of new uses for old pharmaceuticals or in the development of innovative and intelligent nanomedicines for neglected diseases. Liposomes, solid lipid nanoparticles, nanoemulsions, polymeric nanoparticles, metallic nanoparticles, quantum dots, carbon dots and carbon nanotubes were the focus of the current advances. In this direction, we have focused this overview on new advances in diagnostic assays as nanobiosensors, antivirus and nanoinsecticides on Aedes aegyptis control.

show abstract

Untitled

Abstract: Nanoparticles have been shown to be efficient in concentrating AZT in the intestinal epithelium and gut-associated lymphoid tissues, supporting the view that these particles may represent a promising carrier to treat specifically the GI reservoir of HIV.

Cited by 61 publications

References 25 publications

Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment

Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment

Biophysical characterization of small molecule antiviral-loaded nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application

Nanobiotechnology Solutions againstAedes aegypti

Contact Info

Product

Resources

About